Loading…
← CockpitCompetitor Analysis › GLENMARK.NS Glenmark PharmaceuticalsOpen in the cockpit ↗

Glenmark PharmaceuticalsGLENMARK.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian pharma maker of branded generics in emerging markets and US generics, focused on respiratory, dermatology and diabetes.

≈ India's smaller Teva with a biologics spin-offMomentum leader 84
Mkt cap
$7.98B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$25.2M
20-day average traded
Fwd P/E
33.1×
forward earnings
ROIC−WACC
+4.4 pp
WACC 13.1%
Hurdle
+18 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · INR₹2,646
1D+1.2%
1W-1.2%
1M+19.7%
3M+14.8%
6M+10.0%
YTD+30.0%
1Y+43.2%
ATR %3.0%
Beta0.89
52w lowhigh2.5% off high

What Glenmark Pharmaceuticals does

Indian pharma maker of branded generics in emerging markets and US generics, focused on respiratory, dermatology and diabetes.

Sells branded and generic medicines, with India and emerging markets giving the steadier income and US generics adding volume. In 2023 it sold most of its active-ingredient business, Glenmark Life Sciences, to Nirma. A blood-cancer antibody from its innovation arm, Ichnos, was licensed to AbbVie in 2025.

In one line: India's smaller Teva with a biologics spin-off.

Products and services

  • India branded formulations
  • US generics
  • Emerging markets branded generics
  • Respiratory (inhalers)

Customers

  • Indian retail pharmacies
  • US distributors/pharmacies
  • Emerging-market hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded generics + US generics
  • Respiratory/dermatology specialty

What could go right

  • US generic approvals
  • Respiratory/derma brand growth in India

What could go wrong

  • US pricing pressure
  • Debt from biologics R&D spend

Moat: narrow (brand, distribution). Established respiratory/dermatology brands in India and a filed US generics pipeline.

Headquarters: Mumbai, India · Founded: 1977 · Employees: 17,782

Named competitors

Glenmark Pharmaceuticals at a glance

Size Glenmark Pharmaceuticals (GLENMARK.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $7.98B, the 146th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,646 on 18 Nov 2026.

Performance Over six months the shares gained 10.0%, against +4.4% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 0.1% over the last twelve months (peer median +15.7%); the operating margin is 16.6% (peer median 13.8%).

Valuation It trades at 33.1× forward earnings against a peer median of 19.2× (6th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.4 points above its cost of capital (13.1% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026GLENMARK.NS 111Peer median 107
Six months, rebased to 100: Glenmark Pharmaceuticals against the median of its 20 peers (local-currency closes).

Glenmark Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹159B₹170B₹133B₹118B₹116B
Revenue growth—+27%+13%+2%—
Gross profit₹65.7B₹74.6B₹48.2B₹32.6B₹36.3B
EBITDA₹33.0B₹40.2B₹23.8B₹12.3B₹16.7B
Net income₹14.5B₹13.6B₹10.5B-₹15.0B₹2.97B
Free cash flown/a₹19.4B-₹17.3B-₹16.6B-₹2.71B
Capital expendituren/a₹13.6B₹7.51B₹9.15B₹6.08B
Total debt₹14.1B₹5.94B₹24.7B₹12.3B₹46.1B

Quarterly statements and history in the cockpit →

Glenmark Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-40%-20%0%+20%ALK-BALKS2196601607RYTMPTGXAMRX4151GRFPRAXKNSACORT002821CYTKIBRXBANB9926HLUN-AMDGLGLENMARK.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Glenmark Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×ALK-B2196PTGXKNSACORT4528MDGLGLENMARK.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Glenmark Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ALK-BALKS2196601607PTGXAMRX4151GRFKNSACORTGLENMARK.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Glenmark Pharmaceuticals is the large dot.

Glenmark Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (GLENMARK.NS vs CIPLA.NS vs LUPIN.NS vs TORNTPHARM.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Glenmark Pharmaceuticals GLENMARK.NS$7.98B+10%0%17%33.1×27.3%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Alembic Pharmaceuticals APLLTD.NS$2.20B+39%+20%12%25.0×26.7%

How Glenmark Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Glenmark Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureGLENMARK.NSPeer medianRank in peer set
1-month return+19.7%+1.7%3rd highest of 21
6-month return+10.0%+4.4%10th highest of 21
Distance from 52-week high-2.5%-13.5%2nd highest of 21
Revenue growth (TTM)-0.1%+15.7%3rd lowest of 21
Operating margin16.6%13.8%8th highest of 20
Forward P/E33.1×19.2×6th most expensive of 14
Growth the price implies (Req g, 7 yrs)27.3%8.8%2nd most demanding of 13
Growth delivered (Del g)+9.4%+9.0%6th highest of 13
Hurdle (Req g minus delivered)+17.9 pp-2.7 pp2nd most demanding of 13
ROIC minus cost of capital+4.4 pp+1.6 pp7th highest of 18
EV / EBITDA22.6×19.1×7th cheapest of 13
Net debt / EBITDA0.0×-0.1×7th least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a

Questions

Who are Glenmark Pharmaceuticals's main competitors?
Named competitors: Cipla (CIPLA.NS), Lupin (LUPIN.NS), Torrent Pharmaceuticals (TORNTPHARM.NS), Sun Pharmaceutical (SUNPHARMA.NS), Alembic Pharmaceuticals (APLLTD.NS). The cockpit's measured peer set (industry) also includes ALK-abello A/S (ALK-B.CO), Alkermes Public (ALKS), Shanghai Fosun Pharmaceutical (Group) (2196.HK), Shanghai Pharmaceuticals (601607.SS), Rhythm Pharmaceuticals (RYTM), Protagonist Therapeutics (PTGX).
Is Glenmark Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 33.1× against a peer median of 19.2×, 6th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Glenmark Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +10.0% against +4.4% for the median peer; over one year +43.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.